Apogee Therapeutics' Zumilokibart Shows Strong Phase 2 Results, Secures Blackstone Funding Through Commercialization
APGE sits 95% above its 52-week low of $34.34.
Summary
Apogee Therapeutics reported highly positive 16-week Part B Phase 2 results for zumilokibart in moderate-to-severe atopic dermatitis, with the mid-dose achieving 65.9% EASI-75 (41.9% placebo adjusted) and meeting all primary and secondary endpoints. The company plans to advance zumilokibart into Phase 3 trials in the second half of 2026. This strong clinical progress is further bolstered by a strategic financing collaboration with Blackstone Life Sciences, which is expected to fund zumilokibart through commercialization across its indications, significantly de-risking the program. This follows the positive 52-week Part A data reported in March and the company's strong cash position. Phase 3 trials for atopic dermatitis are expected in 2H 2026.
At the time of this announcement, APGE was trading at $67.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $34.34 to $95.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.